Unique ID issued by UMIN | UMIN000032423 |
---|---|
Receipt number | R000036973 |
Scientific Title | Phase II study of additional indication on extreme hypofractionated stereotactic body radiation therapy for prostate cancer |
Date of disclosure of the study information | 2018/05/01 |
Last modified on | 2022/03/26 12:54:48 |
Phase II study of additional indication on extreme hypofractionated stereotactic body radiation therapy for prostate cancer
Phase II study of additional indication on extreme hypofractionated stereotactic body radiation therapy for prostate cancer
Phase II study of additional indication on extreme hypofractionated stereotactic body radiation therapy for prostate cancer
Phase II study of additional indication on extreme hypofractionated stereotactic body radiation therapy for prostate cancer
Japan |
Prostate cancer
Urology | Radiology |
Malignancy
NO
To explore the safety and efficacy of extreme hypofractionated stereotactic body radiation therapy for localized prostate cancer expanded indication to high risk group
Safety,Efficacy
Exploratory
Phase II
Incidence of 5 year chronic adverse events
Incidence of acute adverse events, Incidence of 5 year biochemical failure free survival, Incidence of 5 year clinical failure free survival, Incidence of 5 year overall survival
Interventional
Single arm
Non-randomized
Open -no one is blinded
Historical
1
Treatment
Device,equipment |
Extreme hypofractionated stereotactic body radiation therapy
50 | years-old | <= |
80 | years-old | >= |
Male
(1) Histologically proved prostate adenocarcinoma
(2) Low or intermediate or highg risk prostate cancer (T1-T3aN0M0 and PSA=<50 and GS:6-10)
(3) 50y.o. =< age =< 80 y.o.
(4) ECOG performance status 0-1
(5) Posible to insert fiducial gold markers
(6) Written informed consent
(1) Cancer patients with a duplication of activity
(2) Patients with severe or uncontrollable diabetes
(3) Serious medical complications (uncontrollable collagen disease, heart disease, interstitial pneumonia, liver cirrhosis, etc.)
(4) Mental diseases which prevent from registration of this trial
(5) History of pelvic radiation therapy
(6) History of pelvic surgery
(7) History of prostate surgery including TUR-P and HIFU
(8) History of chemotherapy for prostate cancer
(9) Patients with inflammatory bowel disease
(10) Patients treated with anticoagulant
(11) IPSS => 20
(12) Persons who are judged inappropriate by the researcher
30
1st name | |
Middle name | |
Last name | Takeshi Akiba |
Tokai university school of medicine
Radiation oncology
143 shimokasuya isehara kanagawa japan
0463-93-1121
takiba@is.icc.u-tokai.ac.jp
1st name | |
Middle name | |
Last name | Takeshi Akiba |
Tokai university school of medicine
Radiation oncology
143 shimokasuya isehara kanagawa japan
0463-93-1121
takiba@is.icc.u-tokai.ac.jp
Tokai university
Tokai university
Other
NO
2018 | Year | 05 | Month | 01 | Day |
Unpublished
Terminated
2018 | Year | 02 | Month | 20 | Day |
2018 | Year | 02 | Month | 20 | Day |
2018 | Year | 05 | Month | 01 | Day |
2022 | Year | 03 | Month | 31 | Day |
2018 | Year | 04 | Month | 28 | Day |
2022 | Year | 03 | Month | 26 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000036973
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |